Publication Date:
2014-11-28
Description:
Human tumours typically harbour a remarkable number of somatic mutations. If presented on major histocompatibility complex class I molecules (MHCI), peptides containing these mutations could potentially be immunogenic as they should be recognized as 'non-self' neo-antigens by the adaptive immune system. Recent work has confirmed that mutant peptides can serve as T-cell epitopes. However, few mutant epitopes have been described because their discovery required the laborious screening of patient tumour-infiltrating lymphocytes for their ability to recognize antigen libraries constructed following tumour exome sequencing. We sought to simplify the discovery of immunogenic mutant peptides by characterizing their general properties. We developed an approach that combines whole-exome and transcriptome sequencing analysis with mass spectrometry to identify neo-epitopes in two widely used murine tumour models. Of the 〉1,300 amino acid changes identified, approximately 13% were predicted to bind MHCI, a small fraction of which were confirmed by mass spectrometry. The peptides were then structurally modelled bound to MHCI. Mutations that were solvent-exposed and therefore accessible to T-cell antigen receptors were predicted to be immunogenic. Vaccination of mice confirmed the approach, with each predicted immunogenic peptide yielding therapeutically active T-cell responses. The predictions also enabled the generation of peptide-MHCI dextramers that could be used to monitor the kinetics and distribution of the anti-tumour T-cell response before and after vaccination. These findings indicate that a suitable prediction algorithm may provide an approach for the pharmacodynamic monitoring of T-cell responses as well as for the development of personalized vaccines in cancer patients.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Yadav, Mahesh -- Jhunjhunwala, Suchit -- Phung, Qui T -- Lupardus, Patrick -- Tanguay, Joshua -- Bumbaca, Stephanie -- Franci, Christian -- Cheung, Tommy K -- Fritsche, Jens -- Weinschenk, Toni -- Modrusan, Zora -- Mellman, Ira -- Lill, Jennie R -- Delamarre, Lelia -- England -- Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Genentech, South San Francisco, California 94080, USA. ; Immatics Biotechnologies GmbH, 72076 Tubingen, Germany.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/25428506" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
CD8-Positive T-Lymphocytes/immunology
;
Cancer Vaccines/immunology
;
Cell Line, Tumor
;
Exome/*genetics
;
Female
;
Gene Expression Profiling
;
Immunity, Cellular/immunology
;
Immunogenetic Phenomena/*genetics
;
Immunoprecipitation
;
*Mass Spectrometry
;
Mice
;
Mice, Inbred C57BL
;
Models, Molecular
;
*Mutation
;
Neoplasms/*genetics/immunology
;
Peptides/genetics
;
Protein Structure, Tertiary
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
